ImmunityBio (IBRX) Jefferies London Healthcare Conference 2025 summary

Strategic vision and company progress

• Focus on combination therapies for oncology and infectious diseases, following a vision set decades ago by Dr. Patrick Soon-Shiong.

• The next five years, especially 2025 and 2026, are seen as pivotal for growth and global expansion.

• Emphasis on patient impact and becoming a global company with strong international partnerships.

ANKTIVA approval, uptake, and differentiation

• ANKTIVA became the first IL-15 approved in a decade, marking a major milestone.

• Uptake accelerated after J-code implementation, providing reimbursement certainty for urologists.

• ANKTIVA stands out for high pathological complete response rates, long duration of response, and nurse-administered dosing, enabling higher patient throughput.

Addressing BCG shortage and regulatory pathway

• Partnership with Serum Institute of India to bring recombinant BCG to the U.S., addressing supply issues.

• FDA requested an expanded access program for recombinant BCG, with hundreds of patients treated and no unexpected adverse events.

• Ongoing collaboration with FDA, aiming for a potential approval pathway by 2026.